Johnson & Johnson agreed to buy eye disease biotech Ollin for $2.2 billion upfront

Summary
Blackstone Life Sciences will pay $750 million to fully fund Phase 3 development of Ollin's lead drug candidate, OLN324
Description from Quartz.
Who is covering this
-
Johnson & Johnson agreed to buy eye disease biotech Ollin for $2.2 billion upfront
Blackstone Life Sciences will pay $750 million to fully fund Phase 3 development of Ollin's lead drug candidate, OLN324
Comments
Comments need JavaScript.